Small-cell lung cancer. Diagnostic and therapeutic recommendations of Polish Lung Cancer Group

被引:0
|
作者
Krzakowski, Maciej [1 ]
Orlowski, Tadeusz [2 ]
Roszkowski, Kazimierz [2 ]
Reinfuss, Marian [3 ]
Olszewski, Wlodzimierz [1 ]
Ramlau, Rodryg [4 ]
Kowalski, Dariusz [1 ]
Konopa, Krzysztof [5 ]
Jassem, Jacek [5 ]
Jankowska, Renata [6 ]
Kozielski, Jerzy [7 ]
Wojtukiewicz, Marek [8 ]
Drosik, Kazimierz [9 ]
Koralewski, Piotr [10 ]
机构
[1] Inst Warszawie, Ctr Onkol, Warsaw, Poland
[2] Inst Chorob Pluc & Gruzlicy Warszawie, Warsaw, Poland
[3] Inst Krakowie, Ctr Onkol, Krakow, Poland
[4] Wielkopolskie Ctr Chorob Pluc & Gruzlicy Poznaniu, Poznan, Poland
[5] Akad Medyczna Gdansku, Gdansk, Poland
[6] Akad Med Wroclawiu, Wroclaw, Poland
[7] Akad Med Zabrzu, Zabrze, Poland
[8] Akad Med Bialymstoku, Bialystok, Poland
[9] Wojewodzki Osrodek Onkol Opolu, Opole, Poland
[10] Wojewodzki Szpital Specjalisty Krakowie, Krakow, Poland
来源
ONCOLOGY IN CLINICAL PRACTICE | 2007年 / 3卷 / 01期
关键词
small-cell lung cancer; diagnosis; staging; recommendations; chemotherapy; radiotherapy; surgical treatment;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Small-cell lung cancer is characterised by an aggressive course with high tendency for early dissemination. At presentation, patients are usually symptomatic and with hilar or mediastinal mass at radiography. Staging should be focused on identifying any evidence of distant spread. Chemotherapy including cisplatin and etoposide is a cornerstone of treatment for all patients. Limited-stage disease should be managed by chemotherapy combined with concurrent chest irradiation. All patients who achieve complete response should be considered for elective cranial irradiation. Surgical treatment may be used in highly selected patients with TNM stage I disease, and surgery should always be combined with chemotherapy. Extensive-stage disease should be managed by multi-agent chemotherapy alone. Long-term survivors should undergo careful monitoring for development of a second primary tumour.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [31] Circulating endothelial cells and microparticles as diagnostic and prognostic biomarkers in small-cell lung cancer
    Najjar, Fadi
    Alammar, Moosheer
    Al-Massarani, Ghassan
    Almalla, Nissreen
    Japawe, Abdulmunim
    Ikhtiar, Adnan
    LUNG CANCER, 2018, 124 : 23 - 30
  • [32] Small-cell lung cancer: current news in 2008
    Fournel, Pierre
    ONCOLOGIE, 2009, 11 : S19 - S22
  • [33] SEOM clinical guidelines for the treatment of small-cell lung cancer 2013
    M. Dómine Gómez
    T. Morán Bueno
    A. Artal Cortés
    J. Remon Masip
    P. Lianes Barragán
    Clinical and Translational Oncology, 2013, 15 : 985 - 990
  • [35] Stage I and II Small-Cell Lung Cancer-New Challenge for Surgery
    Doerr, Fabian
    Stange, Sebastian
    Michel, Maximilian
    Schlachtenberger, Georg
    Menghesha, Hruy
    Wahlers, Thorsten
    Hekmat, Khosro
    Heldwein, Matthias B.
    LUNG, 2022, 200 (04) : 505 - 512
  • [36] SEOM clinical guidelines for the treatment of small-cell lung cancer 2013
    Domine Gomez, M.
    Moran Bueno, T.
    Artal Cortes, A.
    Remon Masip, J.
    Lianes Barragan, P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2013, 15 (12) : 985 - 990
  • [37] A review of first-line treatment for small-cell lung cancer
    Murray, Nevin
    Turrisi, Andrew T., III
    JOURNAL OF THORACIC ONCOLOGY, 2006, 1 (03) : 270 - 278
  • [38] Small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
    Sorensen, M.
    Felip, E.
    ANNALS OF ONCOLOGY, 2009, 20 : 71 - 72
  • [39] Timing of treatment in small-cell lung cancer
    Shruti Bhandari
    Danh Pham
    Christina Pinkston
    Malgorzata Oechsli
    Goetz Kloecker
    Medical Oncology, 2019, 36
  • [40] Uterine metastasis of a small-cell lung cancer
    Chargari, C.
    Vedrine, L.
    REVUE DE MEDECINE INTERNE, 2008, 29 (07): : 591 - 592